瑞舒伐他汀及辛伐他汀对心肌梗死患者C反应蛋白及基质金属蛋白酶-9的影响

中华急诊医学杂志2012年8月第21卷第8期Chin J Emerg Med,August 2012,Vol.21,No.8

P892-894

【摘要】目的 观察瑞舒伐他汀及辛伐他汀对心肌梗死患者血清C反应蛋白及基质金属蛋白酶-9水平的影响及比较二者的作用。方法 选取自2010年9月至2012年1月收住河南中医学第一附属医院的心肌梗死患者82例，诊断均符合2007年版急性心肌梗死的诊断和治疗指南标准，发病时间均在24 h内，选此82例心肌梗死患者作为实验组，同期选取82例健康人为对照组。将82例心肌梗死患者随机分为2组：分别为：①辛伐他汀组（辛伐他汀+常规用药）；②瑞舒伐他汀组（瑞舒伐他汀+常规用药）。分别测定治疗前后血浆高敏C反应蛋白、基质金属蛋白酶-9的浓度。结果 急性心肌梗死患者血浆高敏C反应蛋白、基质金属蛋白酶-9的测定值均高于对照组(P＜0.01)；瑞舒伐他汀组及辛伐他汀组治疗后血浆高敏C反应蛋白和基质金属蛋白酶－9的测定值均低于治疗前水平(P＜0.01)，且瑞舒伐他汀组与辛伐他汀组相比，更能降低患者C反应蛋白和基质金属蛋白酶-9水平，二者差异具有统计学意义(P＜0.01)。结论 瑞舒伐他汀较辛伐他汀相比，更能降低心肌梗死患者血清C反应蛋白及基质金属蛋白酶-9水平。

【关键词】瑞舒伐他汀；辛伐他汀；C反应蛋白；基质金属蛋白酶-9

The comparison of the effect of rosuvastatin and simvastatin on myocardial infarction in patients with C reactive protein and matrix metalloproteinase-9 YAN Bao-jian. Emergency Department, the First Affiliated Hospital of Henan College of TCM, Zhengzhou 450002 China

【Abstract】Objective To the difference between the effects which rosuvastatin and simvastatin make in patients of myocardial infarction serum c-reactive protein and matrix metalloproteinases-9 levels of influence. Methods Select from September 2010 to January 2012 were of our 82 patients with myocardial infarction, diagnosis which conform to the 2007 version of acute myocardial infarction in the diagnosis and treatment of guide standard, come on time in 24 h are within, choose the 82 cases of myocardial infarction patients for the test group in that same period, select 82 cases for health in the control group. 82 cases of myocardial infarction patients were randomly divided into 2 groups: respectively :①simvastatin group ( simvastatin + conventional medicine );②rosuvastatin group (rosuvastatin + conventional medicine ). Were measured before and after treatment of plasma high-sensitivity C reactive protein, matrix metalloproteinases-9 concentration. Methods 60 cases of healthy people in the control period. Results In patients with acute myocardial infarction plasma high-sensitivity C reactive protein, matrix metalloproteinases-9 determination value are higher than that of control group ( P＜0.01 ); the rosuvastatin group and simvastatin group after the treatment of plasma high-sensitivity C reactive protein and matrix metalloproteinases-9 determination value were obviously lower than those before therapy level (P＜0.01), And rosuvastatin compared with simvastatin can reduce the patients with C reactive protein and matrix metalloproteinases-9 level, two has statistics difference (P＜0.01 ).Conclusions Rosuvastatin can reduce the myocardial infarction patient blood serum C response protein and matrix metalloproteinases-9 levels better than that of simvastatin.